Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120
- PMID: 1718036
- DOI: 10.1126/science.1718036
Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120
Abstract
The spectrum of human immunodeficiency virus type 1 (HIV-1) isolates neutralized by antibodies from HIV-1-infected humans is broader than the spectrum of isolates neutralized by sera from animals immunized with purified gp120 subunits. This broader neutralization was due, in part, to the presence of antibodies to conserved gp120 conformational epitopes. Purified conformation-dependent gp120-specific human antibodies neutralized a wider range of virus isolates than human antibodies directed to linear determinants in gp120 and were also responsible for the majority of the gp120-specific CD4-blocking activity of HIV-1-infected human sera. A gp120 subunit vaccine that effectively presents these conformation-dependent neutralization epitopes should protect against a broader range of HIV-1 variants than a vaccine that presents exclusively linear determinants.
Similar articles
-
Importance of conformation on the neutralizing antibody response to HIV-1 gp120.Biotechnol Ther. 1991;2(1-2):63-89. Biotechnol Ther. 1991. PMID: 1726963
-
Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.J Virol. 1998 Dec;72(12):9656-67. doi: 10.1128/JVI.72.12.9656-9667.1998. J Virol. 1998. PMID: 9811699 Free PMC article.
-
Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.J Virol. 2018 Feb 12;92(5):e01779-17. doi: 10.1128/JVI.01779-17. Print 2018 Mar 1. J Virol. 2018. PMID: 29237828 Free PMC article.
-
Structural Basis for Epitopes in the gp120 Cluster A Region that Invokes Potent Effector Cell Activity.Viruses. 2019 Jan 16;11(1):69. doi: 10.3390/v11010069. Viruses. 2019. PMID: 30654465 Free PMC article. Review.
-
HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.AIDS. 1995;9 Suppl A:S117-36. AIDS. 1995. PMID: 8819579 Review. No abstract available.
Cited by
-
Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.J Virol. 2004 Jun;78(11):5983-95. doi: 10.1128/JVI.78.11.5983-5995.2004. J Virol. 2004. PMID: 15140996 Free PMC article.
-
Vertical Transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodies.J Clin Invest. 1995 Feb;95(2):732-7. doi: 10.1172/JCI117720. J Clin Invest. 1995. PMID: 7860754 Free PMC article. Clinical Trial.
-
Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.J Virol. 1994 Apr;68(4):2624-31. doi: 10.1128/JVI.68.4.2624-2631.1994. J Virol. 1994. PMID: 7511176 Free PMC article.
-
Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity.J Virol. 1994 Sep;68(9):5395-402. doi: 10.1128/JVI.68.9.5395-5402.1994. J Virol. 1994. PMID: 7520089 Free PMC article.
-
Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.J Virol. 1995 Oct;69(10):6342-51. doi: 10.1128/JVI.69.10.6342-6351.1995. J Virol. 1995. PMID: 7666535 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials